JI-101 is primarily investigated for its potential therapeutic applications in cancer treatment. It functions as a multi-kinase inhibitor, targeting key signaling pathways involved in tumor growth and angiogenesis. Research suggests it may be effective in inhibiting EphB4, vascular endothelial growth factor receptor 2 (VEGFR2), and platelet-derived growth factor receptor β (PDGFRβ), which are critical for cancer cell proliferation and blood vessel formation. Preclinical studies have shown promise in reducing tumor growth in various cancer models, particularly in renal cell carcinoma and other solid tumors. Its application is being explored to enhance the efficacy of existing therapies or as a standalone treatment for resistant cancers. Clinical trials are ongoing to evaluate its safety and effectiveness in human patients.